echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The technology for treating Alzheimer's disease has been certified as a breakthrough medical device by the FDA

    The technology for treating Alzheimer's disease has been certified as a breakthrough medical device by the FDA

    • Last Update: 2022-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 2, 2021, Renew Bioscience announced that a medical device named Cerezen has been granted breakthrough medical device designation by the US FDA for the treatment of mild cognitive impairment (MCI) caused by Alzheimer’s disease, and Alzheimer's type mild dementia


    An important risk factor for Alzheimer's disease-related cognitive impairment and dementia is the patient's poor vascular health.


    Cerezen uses external counterpulsation (External Counterpulsation, ECP) ​​therapy, which can enhance the patient's blood flow and overall cardiovascular system efficiency


    ▲Cerezen's steps and mechanism of action (picture source: Renew Bioscience's official website)

    Reference materials:

    [1] FDA grants Breakthrough status for Alzheimer's treatment.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.